ClinicalTrials.Veeva

Menu

Measurement of Serum microRNA in Acne Vulgaris Patient

S

South Valley University

Status

Not yet enrolling

Conditions

Acne Vulgaris

Treatments

Other: measure serum MicroRNA in acne vulgaris

Study type

Observational

Funder types

Other

Identifiers

NCT05885217
serum microRNA

Details and patient eligibility

About

The aim of the study is to:

  1. Evaluation of serum microRNA in acne vulgaris and compare to control group
  2. Evaluate correlation with acne vulgaris severity

Full description

Acne vulgaris is a common chronic skin disease involving blockage and inflammation of pilosebaceous units.

Acne vulgaris is characterized by non-inflammatory, open or closed comedones and by Inflammatory lesions include papules, pustules and nodules. Affecting mostly the face but also the back and chest.

Acne vulgaris may have a psychological impact on any patient, regardless of the severity or the grade of the disease.

Prevalence of self-reported acne was 34.7%. Females significantly reported acne more frequently than males (39.1% vs. 30.3%) Prevalence of clinically confirmed acne was 24.4%, with higher rates among females (28.6%) than males (20.2%).(4) the pathogenesis result from increased sebum production (due to increased activity of androgens and (IGF-1), excessive deposition of keratin in pilosebaceous follicles leading to comedo formation, colonization of the follicle by Propionibacterium acnes bacteria, and the local release of pro-inflammatory chemicals in the skin through certain inflammatory mechanisms.

recently, Inflammation is a key feature in the pathogenesis of acne vulgaris , with various chemokines and cytokines that contribute to fuel a vicious cycle.

In addition, genetics is also a key factor in the pathophysiology of acne. MicroRNAs(MiRNAs) are a class of endogenous, short (19-23 nucleotides in length), which regulate the expression of genes via translational repression or degradation of target messenger RNAs.Recently, the role of miRNAs has also been reviewed for the pathogenesis of various inflammatory skin conditions such as psoriasis, eczema, atopic dermatitis and toxic epidermal necrolysis.

MiRNAs are present not only in the intracellular space, but also in extracellular spaces such as serum, urine, and saliva. This study is the first to evaluate microRNA in serum of acne vulgaris patients.

Enrollment

120 estimated patients

Sex

All

Ages

10 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

    1. Healthy persons of both sexes with mild, moderate and severe acne vulgaris.
    1. Patients with acne vulgaris not receiving any topical or systemic treatments for acne at least 6 months

Exclusion criteria

    1. Pregnant and lactating women
    1. Patients with history of cardiovascular disorder, renal disease, malignancy, chronic liver disease
    1. Patients with history of depression or mental illness
    1. Diabetes type 2
    1. Obesity
    1. Patient with history of melasma, psoriasis, eczema, atopic dermatitis and toxic epidermal necrolysis.

Trial design

120 participants in 4 patient groups

group 1
Description:
mild form of acne vulgaris
Treatment:
Other: measure serum MicroRNA in acne vulgaris
group2
Description:
moderate form of acne vulgaris
Treatment:
Other: measure serum MicroRNA in acne vulgaris
group 3
Description:
severe form of acne vulgaris
Treatment:
Other: measure serum MicroRNA in acne vulgaris
group 4
Description:
control group
Treatment:
Other: measure serum MicroRNA in acne vulgaris

Trial contacts and locations

0

Loading...

Central trial contact

soher Abdelhamid Ali, Lecturer; Alshayma Gamal Fouad, doctor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems